Transdermal Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Transdermal Drug Delivery Pipeline Market Report Overview

Transdermal drug delivery devices are medicated adhesive patches placed on the skin to deliver a specific dose of medication through the skin into the bloodstream. The Transdermal Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Segments ·        Active Formulations

·        Passive Formulations

Key Territories ·        The US

·        Europe

·        South Korea

·        Canada

·        Australia

Key Regulatory Paths ·        CE

·        510(k)

·        MDITAC

·        MDL

·        NMPA

Leading Companies ·        3P Biotechnologies Inc.

·        4P Therapeutics LLC

·        Abionic SA

·        Actuated Medical Inc.

·        Adynxx Inc.

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Transdermal Drug Delivery Pipeline Market by Segments

The key segments in the transdermal drug delivery pipeline market are active formulations and passive formulations. As of December 2023, active formulations accounted for the highest number of pipeline products.

Transdermal Drug Delivery Pipeline Market Analysis by Segments, 2023 (%)

Transdermal Drug Delivery Pipeline Market Analysis by Segments, 2023 (%)

Buy the Full Report for More Segment Insights into the Transdermal Drug Delivery Pipeline Market

Download a Free Report Sample

Transdermal Drug Delivery Pipeline Market Segmentation by Territories

A few of the key territories for transdermal drug delivery pipeline products are the US, Europe, South Korea, Canada, and Australia. As of December 2023, the US accounted for the highest number of pipeline products.

Transdermal Drug Delivery Pipeline Market Analysis by Territories, 2023 (%)

Transdermal Drug Delivery Pipeline Market Analysis by Territories, 2023 (%)

Buy the Full Report for More Territory Insights into the Transdermal Drug Delivery Pipeline Market

Download a Free Report Sample

Transdermal Drug Delivery Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths followed by the transdermal drug delivery pipeline market are CE, 510(k), MDITAC, MDL, and NMPA. As of December 2023, CE was the most followed pathway for pipeline products in the market.

Transdermal Drug Delivery Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Transdermal Drug Delivery Pipeline Market Analysis by Regulatory Paths, 2023 (%)

Buy the Full Report for More Regulatory Path Insights into the Transdermal Drug Delivery Pipeline Market

Download a Free Report Sample

Transdermal Drug Delivery Pipeline Market – Competitive Landscape

A few of the key companies associated with the transdermal drug delivery pipeline market are 3P Biotechnologies Inc., 4P Therapeutics LLC, Abionic SA, Actuated Medical Inc., and Adynxx Inc., among others.

4P Therapeutics LLC: 4P Therapeutics is headquartered in Peachtree Corners, Georgia, the US. It is a drug delivery company engaged in research and development of transdermal drug delivery technologies and medicines. It also offers various services including chemistry, manufacturing, and controls development, preclinical feasibility, and clinical research.

Abionic SA: Abionic is headquartered in Lausanne, Waadt, Switzerland. It is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company’s IVD capsule test offers accurate information about patients’ respiratory allergies from a drop of blood. Its AbioGUIDE offers access to a complete database, showing cross-reactions with other allergens, as well as illustrations.

Transdermal Drug Delivery Pipeline Market Analysis by Companies, 2023

Transdermal Drug Delivery Pipeline Market Analysis by Companies, 2023

Buy the Full Report for More Company Insights into the Transdermal Drug Delivery Pipeline Market

Download a Free Report Sample

Segments Covered in the Report

Transdermal Drug Delivery Pipeline Market Segments Outlook

  • Active Formulations
  • Passive Formulations

Transdermal Drug Delivery Pipeline Market Territories Outlook

  • The US
  • Europe
  • South Korea
  • Canada
  • Australia

Transdermal Drug Delivery Pipeline Market Regulatory Paths Outlook

  • CE
  • 510(k)
  • MDITAC
  • MDL
  • NMPA

Scope

This report provides:

  • Extensive coverage of the Transdermal Drug Delivery under development.
  • Exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
  • Reviews of major players involved in the development of transdermal drug delivery and lists all their pipeline projects.
  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
  • Key clinical trial data of ongoing clinical trials specific to pipeline products.
  • Recent developments in the segment/industry.

Reasons to Buy

The report will enable you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Identify and understand important and diverse types of transdermal drug delivery under development.
  • Develop market-entry and market-expansion strategies.
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.
  • Carry out In-depth analysis of the product’s current stage of development, territory, and estimated launch date.

3P Biotechnologies Inc
4P Therapeutics LLC
Abionic SA
Actuated Medical Inc
Adynxx Inc
Aequus Pharmaceuticals Inc
AerMedX Ltd
Agile Therapeutics Inc
Allergan Ltd
American Chemical Society
AMW GmbH
Amzell BV
Apogee Technology Inc
Asahi Kasei Pharma Corp
ASCIL Biopharm
Avecho Biotechnology Ltd
Avro Life Sciences
BioNxt Solutions Inc.
Boryung Pharmaceutical Co Ltd
Burke Pharmaceuticals LLC
Candesant Biomedical Inc
Carnegie Mellon University
Cassava Sciences Inc
CB Scientific Inc
Cerimon Pharmaceuticals, Inc. (Inactive)
Chrono Therapeutics Inc
Cipla Ltd
Clexio Biosciences Ltd
Corium Inc
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
DBV Technologies SA
DD Therapeutics LLC (Inactive)
Delpor Inc
Dermisonics Inc
Dharma Therapeutics, Inc. (Inactive)
Diomics Corp
Dong-A ST Co Ltd
Drexel University
DURECT Corp
Echo Therapeutics Inc
Emplicure AB
Endo International Plc
Endomimetics LLC
Extend Biosciences Inc
Fe3 Medical Inc
Futura Medical Plc
Georgetown University
Georgia Institute of Technology
Georgia State University
GlobeStar Therapeutics Corp
Henley Ion LLC
Hera Health Solutions
Hisamitsu Pharmaceutical Co Inc
I M Sechenov Moscow State Medical University
Icure Pharmaceutical Inc
ImmunoMatrix LLC
ImmuPatch
Indian Institute of Science
Indian Institute of Technology Bombay
Indian Institute of Technology Hyderabad
InMed Pharmaceuticals Inc
Institute of Materials Research & Engineering
Intercell AG (Inactive)
Interstitial NS
Isis Biopolymer Inc (Inactive)
James J. Peters VA Medical Center
Janisys
Jiaxing Xinwen Biotechnology Co Ltd
Jubilee Biotech
Karolinska Institute
Kindeva Drug Delivery LP
KTH Royal Institute of Technology
Leo Pharma AS
Livzon Pharmaceutical Group Co Ltd
Lohmann Therapie-Systeme AG
Luye Pharma Group Ltd
Magnetar Medical Devices Ltd
Massachusetts Institute of Technology
Mayne Pharma Group Ltd
Medherant Ltd
MEDRx Co Ltd
MedRx, Inc.
Microdermics Inc
Micron Biomedical Inc
Micropoint Technologies Pte Ltd
Mineed Technology Co Ltd
Mycrodose Therapeutics Inc
MyLife Technologies
Nanyang Technological University
National Dental Centre Singapore
National University of Singapore
Nemaura Pharma Ltd
NeuroDerm Ltd
Nexgel Inc
Nitto Denko Corp
North Carolina State University
Nova Graphene Ballistics Inc
Noven Pharmaceuticals Inc
NutriBand Inc
Nuvo Pharmaceuticals Inc
Ohio State University
Osprey Medical Inc
Pantec Biosolutions AG
PassPort Technologies Inc
Pebble Inc
PharmaTher Holdings Ltd
Privo Technologies Inc
Prometheon Pharma LLC
Purdue University
Quadmedicine
Quoin Pharmaceuticals Inc
Radius Health Inc
Rescue Biomedical LLC
Ryah Medtech Inc
Samyang Biopharmaceuticals Corp
Sanofi
Satio Inc
Seelos Therapeutics, Inc.
Shenox Pharmaceuticals LLC
Sichuan Kelun Pharmaceutical Co Ltd
Sinsin Pharmaceutical Co Ltd
SK Chemicals Co Ltd
Skinject Inc
Sorrento Therapeutics Inc
Sparsha Pharma International Pvt Ltd
Sree Chitra Tirunal Institute for Medical Sciences & Technology
Stanford University
Starton Therapeutics Inc
Suzhou Reveda Medical Co Ltd
Swansea University
Syntropharma Ltd
Taho Pharmaceuticals Ltd
Teikoku Pharma USA Inc
tesa Labtec GmbH
Teva Pharmaceutical Industries Ltd
Texas Tech University
The Sheikh Zayed Institute for Pediatric Surgical Innovation
TheraJect Inc
Therapeutic Systems Research Laboratories Inc
TheraSolve NV (Inactive)
Theratech, Inc.
Theris Medical Inc
Thrudermic LLC
Titan Pharmaceuticals Inc
Transcu Group Limited (Inactive)
Transdermal Delivery Solutions Corp
Transdermal Specialties Inc
TransPharma Medical Ltd (Inactive)
Transport Pharmaceuticals Inc
University of Connecticut Health Center
University of Helsinki
University of Hong Kong
University of Illinois at Chicago
University of Iowa
University of South Florida
University of the Philippines Manila
University of the Witwatersrand
University of Tokyo
University of Toronto
University of Washington
Vaxess Technologies Inc
Vaxxas Pty Ltd
Verndari Inc
ViiV Healthcare UK Ltd
Virpax Pharmaceuticals Inc
Vyteris, Inc. (Inactive)
Wellfully Ltd
Xel Pharmaceuticals Inc
Zambon Italia Srl
Z-Cube Srl
Zosano Pharma Corp
Zylo Therapeutics LLC
Zynerba Pharmaceuticals Inc

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 13

|1.2 List of Figures 29

2 Introduction 30

2.1 Transdermal Drug Delivery Overview 30

3 Products under Development 31

3.1 Transdermal Drug Delivery – Pipeline Products by Stage of Development 31

3.2 Transdermal Drug Delivery – Pipeline Products by Segment 32

3.3 Transdermal Drug Delivery – Pipeline Products by Territory 33

3.4 Transdermal Drug Delivery – Pipeline Products by Regulatory Path 35

3.5 Transdermal Drug Delivery – Pipeline Products by Estimated Approval Date 36

3.6 Transdermal Drug Delivery – Ongoing Clinical Trials 37

4 Transdermal Drug Delivery – Pipeline Products under Development by Companies 38

4.1 Transdermal Drug Delivery Companies – Pipeline Products by Stage of Development 38

4.2 Transdermal Drug Delivery – Pipeline Products by Stage of Development 45

5 Transdermal Drug Delivery Companies and Product Overview 53

5.1 3P Biotechnologies Inc Company Overview 53

5.1.1 3P Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview 53

5.2 4P Therapeutics LLC Company Overview 54

5.2.1 4P Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 54

5.3 Abionic SA Company Overview 62

5.3.1 Abionic SA Pipeline Products & Ongoing Clinical Trials Overview 62

5.4 Actuated Medical Inc Company Overview 63

5.4.1 Actuated Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 63

5.5 Adynxx Inc Company Overview 64

5.5.1 Adynxx Inc Pipeline Products & Ongoing Clinical Trials Overview 64

5.6 Aequus Pharmaceuticals Inc Company Overview 65

5.6.1 Aequus Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 65

5.7 AerMedX Ltd Company Overview 69

5.7.1 AerMedX Ltd Pipeline Products & Ongoing Clinical Trials Overview 69

5.8 Agile Therapeutics Inc Company Overview 70

5.8.1 Agile Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 70

5.9 Allergan Ltd Company Overview 73

5.9.1 Allergan Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

5.10 American Chemical Society Company Overview 75

5.10.1 American Chemical Society Pipeline Products & Ongoing Clinical Trials Overview 75

5.11 AMW GmbH Company Overview 76

5.11.1 AMW GmbH Pipeline Products & Ongoing Clinical Trials Overview 76

5.12 Amzell BV Company Overview 77

5.12.1 Amzell BV Pipeline Products & Ongoing Clinical Trials Overview 77

5.13 Apogee Technology Inc Company Overview 78

5.13.1 Apogee Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 78

5.14 Asahi Kasei Pharma Corp Company Overview 79

5.14.1 Asahi Kasei Pharma Corp Pipeline Products & Ongoing Clinical Trials Overview 79

5.15 ASCIL Biopharm Company Overview 80

5.15.1 ASCIL Biopharm Pipeline Products & Ongoing Clinical Trials Overview 80

5.16 Avecho Biotechnology Ltd Company Overview 81

5.16.1 Avecho Biotechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview 81

5.17 Avro Life Sciences Company Overview 84

5.17.1 Avro Life Sciences Pipeline Products & Ongoing Clinical Trials Overview 84

5.18 BioNxt Solutions Inc. Company Overview 86

5.18.1 BioNxt Solutions Inc. Pipeline Products & Ongoing Clinical Trials Overview 86

5.19 Boryung Pharmaceutical Co Ltd Company Overview 89

5.19.1 Boryung Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

5.20 Burke Pharmaceuticals LLC Company Overview 90

5.20.1 Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 90

5.21 Candesant Biomedical Inc Company Overview 92

5.21.1 Candesant Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 92

5.22 Carnegie Mellon University Company Overview 97

5.22.1 Carnegie Mellon University Pipeline Products & Ongoing Clinical Trials Overview 97

5.23 Cassava Sciences Inc Company Overview 98

5.23.1 Cassava Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 98

5.24 CB Scientific Inc Company Overview 99

5.24.1 CB Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 99

5.25 Cerimon Pharmaceuticals, Inc. (Inactive) Company Overview 100

5.25.1 Cerimon Pharmaceuticals, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 100

5.26 Chrono Therapeutics Inc Company Overview 101

5.26.1 Chrono Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 101

5.27 Cipla Ltd Company Overview 102

5.27.1 Cipla Ltd Pipeline Products & Ongoing Clinical Trials Overview 102

5.28 Clexio Biosciences Ltd Company Overview 103

5.28.1 Clexio Biosciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 103

5.29 Corium Inc Company Overview 104

5.29.1 Corium Inc Pipeline Products & Ongoing Clinical Trials Overview 104

5.30 Daewon Pharmaceutical Co Ltd Company Overview 108

5.30.1 Daewon Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 108

5.31 Daewoong Pharmaceutical Co Ltd Company Overview 111

5.31.1 Daewoong Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 111

5.32 DBV Technologies SA Company Overview 112

5.32.1 DBV Technologies SA Pipeline Products & Ongoing Clinical Trials Overview 112

5.33 DD Therapeutics LLC (Inactive) Company Overview 119

5.33.1 DD Therapeutics LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 119

5.34 Delpor Inc Company Overview 120

5.34.1 Delpor Inc Pipeline Products & Ongoing Clinical Trials Overview 120

5.35 Dermisonics Inc Company Overview 122

5.35.1 Dermisonics Inc Pipeline Products & Ongoing Clinical Trials Overview 122

5.36 Dharma Therapeutics, Inc. (Inactive) Company Overview 123

5.36.1 Dharma Therapeutics, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 123

5.37 Diomics Corp Company Overview 124

5.37.1 Diomics Corp Pipeline Products & Ongoing Clinical Trials Overview 124

5.38 Dong-A ST Co Ltd Company Overview 125

5.38.1 Dong-A ST Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 125

5.39 Drexel University Company Overview 126

5.39.1 Drexel University Pipeline Products & Ongoing Clinical Trials Overview 126

5.40 DURECT Corp Company Overview 127

5.40.1 DURECT Corp Pipeline Products & Ongoing Clinical Trials Overview 127

5.41 Echo Therapeutics Inc Company Overview 129

5.41.1 Echo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 129

5.42 Emplicure AB Company Overview 130

5.42.1 Emplicure AB Pipeline Products & Ongoing Clinical Trials Overview 130

5.43 Endo International Plc Company Overview 131

5.43.1 Endo International Plc Pipeline Products & Ongoing Clinical Trials Overview 131

5.44 Endomimetics LLC Company Overview 132

5.44.1 Endomimetics LLC Pipeline Products & Ongoing Clinical Trials Overview 132

5.45 Extend Biosciences Inc Company Overview 133

5.45.1 Extend Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 133

5.46 Fe3 Medical Inc Company Overview 134

5.46.1 Fe3 Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 134

5.47 Futura Medical Plc Company Overview 135

5.47.1 Futura Medical Plc Pipeline Products & Ongoing Clinical Trials Overview 135

5.48 Georgetown University Company Overview 139

5.48.1 Georgetown University Pipeline Products & Ongoing Clinical Trials Overview 139

5.49 Georgia Institute of Technology Company Overview 140

5.49.1 Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 140

5.50 Georgia State University Company Overview 143

5.50.1 Georgia State University Pipeline Products & Ongoing Clinical Trials Overview 143

5.51 GlobeStar Therapeutics Corp Company Overview 144

5.51.1 GlobeStar Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview 144

5.52 Henley Ion LLC Company Overview 145

5.52.1 Henley Ion LLC Pipeline Products & Ongoing Clinical Trials Overview 145

5.53 Hera Health Solutions Company Overview 146

5.53.1 Hera Health Solutions Pipeline Products & Ongoing Clinical Trials Overview 146

5.54 Hisamitsu Pharmaceutical Co Inc Company Overview 147

5.54.1 Hisamitsu Pharmaceutical Co Inc Pipeline Products & Ongoing Clinical Trials Overview 147

5.55 I M Sechenov Moscow State Medical University Company Overview 150

5.55.1 I M Sechenov Moscow State Medical University Pipeline Products & Ongoing Clinical Trials Overview 150

5.56 Icure Pharmaceutical Inc Company Overview 151

5.56.1 Icure Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 151

5.57 ImmunoMatrix LLC Company Overview 158

5.57.1 ImmunoMatrix LLC Pipeline Products & Ongoing Clinical Trials Overview 158

5.58 ImmuPatch Company Overview 159

5.58.1 ImmuPatch Pipeline Products & Ongoing Clinical Trials Overview 159

5.59 Indian Institute of Science Company Overview 161

5.59.1 Indian Institute of Science Pipeline Products & Ongoing Clinical Trials Overview 161

5.60 Indian Institute of Technology Bombay Company Overview 162

5.60.1 Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 162

5.61 Indian Institute of Technology Hyderabad Company Overview 163

5.61.1 Indian Institute of Technology Hyderabad Pipeline Products & Ongoing Clinical Trials Overview 163

5.62 InMed Pharmaceuticals Inc Company Overview 164

5.62.1 InMed Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 164

5.63 Institute of Materials Research & Engineering Company Overview 166

5.63.1 Institute of Materials Research & Engineering Pipeline Products & Ongoing Clinical Trials Overview 166

5.64 Intercell AG (Inactive) Company Overview 167

5.64.1 Intercell AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 167

5.65 Interstitial NS Company Overview 168

5.65.1 Interstitial NS Pipeline Products & Ongoing Clinical Trials Overview 168

5.66 Isis Biopolymer Inc (Inactive) Company Overview 169

5.66.1 Isis Biopolymer Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 169

5.67 James J. Peters VA Medical Center Company Overview 171

5.67.1 James J. Peters VA Medical Center Pipeline Products & Ongoing Clinical Trials Overview 171

5.68 Janisys Company Overview 172

5.68.1 Janisys Pipeline Products & Ongoing Clinical Trials Overview 172

5.69 Jiaxing Xinwen Biotechnology Co Ltd Company Overview 173

5.69.1 Jiaxing Xinwen Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 173

5.70 Jubilee Biotech Company Overview 175

5.70.1 Jubilee Biotech Pipeline Products & Ongoing Clinical Trials Overview 175

5.71 Karolinska Institute Company Overview 176

5.71.1 Karolinska Institute Pipeline Products & Ongoing Clinical Trials Overview 176

5.72 Kindeva Drug Delivery LP Company Overview 177

5.72.1 Kindeva Drug Delivery LP Pipeline Products & Ongoing Clinical Trials Overview 177

5.73 KTH Royal Institute of Technology Company Overview 179

5.73.1 KTH Royal Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 179

5.74 Leo Pharma AS Company Overview 180

5.74.1 Leo Pharma AS Pipeline Products & Ongoing Clinical Trials Overview 180

5.75 Livzon Pharmaceutical Group Co Ltd Company Overview 181

5.75.1 Livzon Pharmaceutical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 181

5.76 Lohmann Therapie-Systeme AG Company Overview 182

5.76.1 Lohmann Therapie-Systeme AG Pipeline Products & Ongoing Clinical Trials Overview 182

5.77 Luye Pharma Group Ltd Company Overview 184

5.77.1 Luye Pharma Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 184

5.78 Magnetar Medical Devices Ltd Company Overview 186

5.78.1 Magnetar Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 186

5.79 Massachusetts Institute of Technology Company Overview 187

5.79.1 Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 187

5.80 Mayne Pharma Group Ltd Company Overview 189

5.80.1 Mayne Pharma Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 189

5.81 Medherant Ltd Company Overview 190

5.81.1 Medherant Ltd Pipeline Products & Ongoing Clinical Trials Overview 190

5.82 MEDRx Co Ltd Company Overview 195

5.82.1 MEDRx Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 195

5.83 MedRx, Inc. Company Overview 201

5.83.1 MedRx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 201

5.84 Microdermics Inc Company Overview 202

5.84.1 Microdermics Inc Pipeline Products & Ongoing Clinical Trials Overview 202

5.85 Micron Biomedical Inc Company Overview 203

5.85.1 Micron Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 203

5.86 Micropoint Technologies Pte Ltd Company Overview 205

5.86.1 Micropoint Technologies Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 205

5.87 Mineed Technology Co Ltd Company Overview 206

5.87.1 Mineed Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 206

5.88 Mycrodose Therapeutics Inc Company Overview 207

5.88.1 Mycrodose Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 207

5.89 MyLife Technologies Company Overview 209

5.89.1 MyLife Technologies Pipeline Products & Ongoing Clinical Trials Overview 209

5.90 Nanyang Technological University Company Overview 210

5.90.1 Nanyang Technological University Pipeline Products & Ongoing Clinical Trials Overview 210

5.91 National Dental Centre Singapore Company Overview 211

5.91.1 National Dental Centre Singapore Pipeline Products & Ongoing Clinical Trials Overview 211

5.92 National University of Singapore Company Overview 212

5.92.1 National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 212

5.93 Nemaura Pharma Ltd Company Overview 214

5.93.1 Nemaura Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 214

5.94 NeuroDerm Ltd Company Overview 221

5.94.1 NeuroDerm Ltd Pipeline Products & Ongoing Clinical Trials Overview 221

5.95 Nexgel Inc Company Overview 223

5.95.1 Nexgel Inc Pipeline Products & Ongoing Clinical Trials Overview 223

5.96 Nitto Denko Corp Company Overview 224

5.96.1 Nitto Denko Corp Pipeline Products & Ongoing Clinical Trials Overview 224

5.97 North Carolina State University Company Overview 227

5.97.1 North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 227

5.98 Nova Graphene Ballistics Inc Company Overview 229

5.98.1 Nova Graphene Ballistics Inc Pipeline Products & Ongoing Clinical Trials Overview 229

5.99 Noven Pharmaceuticals Inc Company Overview 230

5.99.1 Noven Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 230

5.100 NutriBand Inc Company Overview 231

5.100.1 NutriBand Inc Pipeline Products & Ongoing Clinical Trials Overview 231

5.101 Nuvo Pharmaceuticals Inc Company Overview 235

5.101.1 Nuvo Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 235

5.102 Ohio State University Company Overview 236

5.102.1 Ohio State University Pipeline Products & Ongoing Clinical Trials Overview 236

5.103 Osprey Medical Inc Company Overview 238

5.103.1 Osprey Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 238

5.104 Pantec Biosolutions AG Company Overview 239

5.104.1 Pantec Biosolutions AG Pipeline Products & Ongoing Clinical Trials Overview 239

5.105 PassPort Technologies Inc Company Overview 243

5.105.1 PassPort Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 243

5.106 Pebble Inc Company Overview 244

5.106.1 Pebble Inc Pipeline Products & Ongoing Clinical Trials Overview 244

5.107 PharmaTher Holdings Ltd Company Overview 245

5.107.1 PharmaTher Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview 245

5.108 Privo Technologies Inc Company Overview 249

5.108.1 Privo Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 249

5.109 Prometheon Pharma LLC Company Overview 250

5.109.1 Prometheon Pharma LLC Pipeline Products & Ongoing Clinical Trials Overview 250

5.110 Purdue University Company Overview 253

5.110.1 Purdue University Pipeline Products & Ongoing Clinical Trials Overview 253

5.111 Quadmedicine Company Overview 256

5.111.1 Quadmedicine Pipeline Products & Ongoing Clinical Trials Overview 256

5.112 Quoin Pharmaceuticals Inc Company Overview 260

5.112.1 Quoin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 260

5.113 Radius Health Inc Company Overview 262

5.113.1 Radius Health Inc Pipeline Products & Ongoing Clinical Trials Overview 262

5.114 Rescue Biomedical LLC Company Overview 263

5.114.1 Rescue Biomedical LLC Pipeline Products & Ongoing Clinical Trials Overview 263

5.115 Ryah Medtech Inc Company Overview 264

5.115.1 Ryah Medtech Inc Pipeline Products & Ongoing Clinical Trials Overview 264

5.116 Samyang Biopharmaceuticals Corp Company Overview 265

5.116.1 Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 265

5.117 Sanofi Company Overview 266

5.117.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 266

5.118 Satio Inc Company Overview 267

5.118.1 Satio Inc Pipeline Products & Ongoing Clinical Trials Overview 267

5.119 Seelos Therapeutics, Inc. Company Overview 268

5.119.1 Seelos Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 268

5.120 Shenox Pharmaceuticals LLC Company Overview 269

5.120.1 Shenox Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 269

5.121 Sichuan Kelun Pharmaceutical Co Ltd Company Overview 273

5.121.1 Sichuan Kelun Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 273

5.122 Sinsin Pharmaceutical Co Ltd Company Overview 274

5.122.1 Sinsin Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 274

5.123 SK Chemicals Co Ltd Company Overview 282

5.123.1 SK Chemicals Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 282

5.124 Skinject Inc Company Overview 283

5.124.1 Skinject Inc Pipeline Products & Ongoing Clinical Trials Overview 283

5.125 Sorrento Therapeutics Inc Company Overview 286

5.125.1 Sorrento Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 286

5.126 Sparsha Pharma International Pvt Ltd Company Overview 287

5.126.1 Sparsha Pharma International Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 287

5.127 Sree Chitra Tirunal Institute for Medical Sciences & Technology Company Overview 290

5.127.1 Sree Chitra Tirunal Institute for Medical Sciences & Technology Pipeline Products & Ongoing Clinical Trials Overview 290

5.128 Stanford University Company Overview 291

5.128.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 291

5.129 Starton Therapeutics Inc Company Overview 293

5.129.1 Starton Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 293

5.130 Suzhou Reveda Medical Co Ltd Company Overview 299

5.130.1 Suzhou Reveda Medical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 299

5.131 Swansea University Company Overview 300

5.131.1 Swansea University Pipeline Products & Ongoing Clinical Trials Overview 300

5.132 Syntropharma Ltd Company Overview 301

5.132.1 Syntropharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 301

5.133 Taho Pharmaceuticals Ltd Company Overview 303

5.133.1 Taho Pharmaceuticals Ltd Pipeline Products & Ongoing Clinical Trials Overview 303

5.134 Teikoku Pharma USA Inc Company Overview 307

5.134.1 Teikoku Pharma USA Inc Pipeline Products & Ongoing Clinical Trials Overview 307

5.135 tesa Labtec GmbH Company Overview 311

5.135.1 tesa Labtec GmbH Pipeline Products & Ongoing Clinical Trials Overview 311

5.136 Teva Pharmaceutical Industries Ltd Company Overview 313

5.136.1 Teva Pharmaceutical Industries Ltd Pipeline Products & Ongoing Clinical Trials Overview 313

5.137 Texas Tech University Company Overview 314

5.137.1 Texas Tech University Pipeline Products & Ongoing Clinical Trials Overview 314

5.138 The Sheikh Zayed Institute for Pediatric Surgical Innovation Company Overview 315

5.138.1 The Sheikh Zayed Institute for Pediatric Surgical Innovation Pipeline Products & Ongoing Clinical Trials Overview 315

5.139 TheraJect Inc Company Overview 316

5.139.1 TheraJect Inc Pipeline Products & Ongoing Clinical Trials Overview 316

5.140 Therapeutic Systems Research Laboratories Inc Company Overview 317

5.140.1 Therapeutic Systems Research Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 317

5.141 TheraSolve NV (Inactive) Company Overview 319

5.141.1 TheraSolve NV (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 319

5.142 Theratech, Inc. Company Overview 320

5.142.1 Theratech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 320

5.143 Theris Medical Inc Company Overview 321

5.143.1 Theris Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 321

5.144 Thrudermic LLC Company Overview 322

5.144.1 Thrudermic LLC Pipeline Products & Ongoing Clinical Trials Overview 322

5.145 Titan Pharmaceuticals Inc Company Overview 323

5.145.1 Titan Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 323

5.146 Transcu Group Limited (Inactive) Company Overview 324

5.146.1 Transcu Group Limited (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 324

5.147 Transdermal Delivery Solutions Corp Company Overview 325

5.147.1 Transdermal Delivery Solutions Corp Pipeline Products & Ongoing Clinical Trials Overview 325

5.148 Transdermal Specialties Inc Company Overview 331

5.148.1 Transdermal Specialties Inc Pipeline Products & Ongoing Clinical Trials Overview 331

5.149 TransPharma Medical Ltd (Inactive) Company Overview 332

5.149.1 TransPharma Medical Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 332

5.150 Transport Pharmaceuticals Inc Company Overview 334

5.150.1 Transport Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 334

5.151 University of Connecticut Health Center Company Overview 335

5.151.1 University of Connecticut Health Center Pipeline Products & Ongoing Clinical Trials Overview 335

5.152 University of Helsinki Company Overview 336

5.152.1 University of Helsinki Pipeline Products & Ongoing Clinical Trials Overview 336

5.153 University of Hong Kong Company Overview 337

5.153.1 University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 337

5.154 University of Illinois at Chicago Company Overview 338

5.154.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 338

5.155 University of Iowa Company Overview 339

5.155.1 University of Iowa Pipeline Products & Ongoing Clinical Trials Overview 339

5.156 University of South Florida Company Overview 340

5.156.1 University of South Florida Pipeline Products & Ongoing Clinical Trials Overview 340

5.157 University of the Philippines Manila Company Overview 342

5.157.1 University of the Philippines Manila Pipeline Products & Ongoing Clinical Trials Overview 342

5.158 University of the Witwatersrand Company Overview 343

5.158.1 University of the Witwatersrand Pipeline Products & Ongoing Clinical Trials Overview 343

5.159 University of Tokyo Company Overview 344

5.159.1 University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 344

5.160 University of Toronto Company Overview 345

5.160.1 University of Toronto Pipeline Products & Ongoing Clinical Trials Overview 345

5.161 University of Washington Company Overview 346

5.161.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 346

5.162 Vaxess Technologies Inc Company Overview 347

5.162.1 Vaxess Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 347

5.163 Vaxxas Pty Ltd Company Overview 350

5.163.1 Vaxxas Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 350

5.164 Verndari Inc Company Overview 354

5.164.1 Verndari Inc Pipeline Products & Ongoing Clinical Trials Overview 354

5.165 ViiV Healthcare UK Ltd Company Overview 355

5.165.1 ViiV Healthcare UK Ltd Pipeline Products & Ongoing Clinical Trials Overview 355

5.166 Virpax Pharmaceuticals Inc Company Overview 356

5.166.1 Virpax Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 356

5.167 Vyteris, Inc. (Inactive) Company Overview 360

5.167.1 Vyteris, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 360

5.168 Wellfully Ltd Company Overview 361

5.168.1 Wellfully Ltd Pipeline Products & Ongoing Clinical Trials Overview 361

5.169 Xel Pharmaceuticals Inc Company Overview 362

5.169.1 Xel Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 362

5.170 Zambon Italia Srl Company Overview 366

5.170.1 Zambon Italia Srl Pipeline Products & Ongoing Clinical Trials Overview 366

5.171 Z-Cube Srl Company Overview 367

5.171.1 Z-Cube Srl Pipeline Products & Ongoing Clinical Trials Overview 367

5.172 Zosano Pharma Corp Company Overview 368

5.172.1 Zosano Pharma Corp Pipeline Products & Ongoing Clinical Trials Overview 368

5.173 Zylo Therapeutics LLC Company Overview 370

5.173.1 Zylo Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 370

5.174 Zynerba Pharmaceuticals Inc Company Overview 371

5.174.1 Zynerba Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 371

6 Transdermal Drug Delivery- Recent Developments 372

6.1 Dec 06, 2023: LTS Receives Grant of $1.2 Million to Support the Development of Thermostable Mrna Formulations for Microneedle Array Patches 372

6.2 Nov 29, 2023: Aequus Reports Third Quarter 2023 Financial Highlights and General Update 372

6.3 Nov 16, 2023: Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles 373

6.4 Nov 15, 2023: Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch 374

6.5 Nov 09, 2023: Camurus Publishes Interim Report Third Quarter 2023 374

6.6 Nov 09, 2023: Camurus Announces Interim Report Third Quarter 2023 375

6.7 Nov 09, 2023: 3M Announces Leadership Changes 375

6.8 Nov 07, 2023: Futura Expands Partnership with M8 Pharmaceuticals For Remainder of Central and South American Region 376

6.9 Nov 07, 2023: Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business 376

6.10 Oct 27, 2023: Nanologica Announces Interim Report Q3 2023 377

6.11 Oct 26, 2023: Lilly to Participate in UBS Biopharma Conference 2023 378

6.12 Oct 25, 2023: Eroxon Granted Marketing Authorisation in Mexico 378

6.13 Oct 24, 2023: 3M Reports Third Quarter 2023 Results; Company Increases Full Year Adjusted Earnings and Cash Flow Expectations 378

6.14 Oct 20, 2023: Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement 379

6.15 Oct 19, 2023: Futura Medical : Eroxon Launches in the United Arab Emirates 379

6.16 Oct 18, 2023: Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP) 380

6.17 Oct 04, 2023: Lilly Announces Leadership Transitions 381

6.18 Oct 04, 2023: Medtronic Names Paolo Di Vincenzo President of the Neuromodulation Business 382

6.19 Oct 02, 2023: European Patent Office grants patent for MED3000 providing protection to 2040 382

6.20 Sep 28, 2023: Teva Announces Changes to Executive Management Team 382

6.21 Sep 27, 2023: Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology 383

6.22 Sep 26, 2023: Satio Receives Funding From ARPA-H to Develop SatioRx a Novel At-home, Remotely Controllable Transdermal Drug Delivery Device 384

6.23 Sep 20, 2023: Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent Technology 384

6.24 Sep 19, 2023: Revance Provides Corporate Update at Investor Day 385

6.25 Sep 12, 2023: Corium Announces Publication of Favorable Adlarity (Donepezil Transdermal System) Skin Irritation Clinical Trial Data 386

6.26 Sep 01, 2023: Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27 387

6.27 Aug 26, 2023: Medtronic Q2 2024 Earnings Estimates Increased by William Blair 387

6.28 Aug 24, 2023: SK Bioscience and Vaxxas partner to develop needle-free typhoid vaccine patch 387

6.29 Aug 23, 2023: 3M Appoints Carrie Cox as Chairman of the Board of Directors of the Independent Health Care Company 388

6.30 Aug 22, 2023: Bryan Hanson Named CEO of 3M’s Health Care Business Group 388

6.31 Aug 09, 2023: Futura Medical : MED3000 Approved for Commercialisation in Saudi Arabia Under the Brand Name Eroxon 390

6.32 Aug 08, 2023: Daewon Pharm Applies for Trial of Patch-Type Obesity Treatment 390

6.33 Aug 08, 2023: Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2024 391

6.34 Aug 01, 2023: Notification of Application for Manufacturing and Marketing Approval of Hp-5070 (Primary Palmar Hyperhidrosis Treatment Drug) In Japan 391

6.35 Jul 25, 2023: Vaxxas Opening Statement to the Standing Committee on Industry, Science and Resources 391

6.36 Jul 19, 2023: This Reproductive Health Company’s Weekly Contraceptive Patch Can Reach Millions of Women Thanks to a Partnership With Afaxys 392

6.37 Jul 18, 2023: Agile Therapeutics Partners with Telehealth Platforms to Expand Access to Weekly Birth Control Patch to Millions of Women 393

6.38 Jul 18, 2023: PharmaTher Announces Positive Research Results for PharmaPatch with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics 394

6.39 Jul 14, 2023: Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA Platform Towards FDA Submission 395

6.40 Jul 13, 2023: SiSaf Announces Appoints Nikos Tzagkarakis as Chief A.I. Officer 395

6.41 Jul 11, 2023: Sumitomo Pharma Announces Executive Changes 396

6.42 Jul 11, 2023: Kindeva Drug Delivery, Chiesi Group, and H&T Presspart Announce Strategic Partnership for Dose Counter Technology Production 396

6.43 Jul 05, 2023: Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2 397

6.44 Jun 28, 2023: Hkumed Invents a Novel Microneedle Array Embedded With Ultrasound-Triggered Antibacterial Nanoparticles Enabling a Breakthrough Treatment for Skin Infection 397

6.45 Jun 26, 2023: Agile Therapeutics Announces the Availability of Twirla to MMCAP Infuse Members 398

6.46 Jun 16, 2023: CS MEDICA Secures Trademark Approval in Canada 398

6.47 Jun 16, 2023: Lannett Successfully Emerges From Chapter 11 in Significantly Stronger Financial Position as the Company Remains on Track Toward Commercialization of Highly Promising Pipeline 399

6.48 Jun 12, 2023: Futura’s Fast-Acting Topical Gel for the Treatment of Erectile Dysfunction Granted Marketing Authorisation by the US FDA for Over the Counter Sale 399

6.49 Jun 12, 2023: Agile Therapeutics Announces New Agreement with vitaCare Prescription Services to Improve Access to Twirla 400

6.50 Jun 05, 2023: Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP) 400

6.51 May 30, 2023: Aequus provides general update and first quarter 2023 financial highlights 401

6.52 May 26, 2023: CS MEDICA Onboards Distributors With First-Year Orders of Dkk

5.6m and Cash Flow Positively Effect by Shorter Lead Times 402

6.53 May 25, 2023: Kopran Announces Audited Financial Results for the Year Ended March 31, 2023 403

6.54 May 18, 2023: Salonpas Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Seventh Consecutive Year 403

6.55 May 17, 2023: Micron Biomedical announces positive measles and rubella vaccination results from first clinical trial of microarray injection-free vaccine delivery in children 404

6.56 May 15, 2023: BioNxt receives approval for European clinical study of Transdermal Rotigotine Patch for Parkinson’s Disease 405

6.57 May 15, 2023: CS MEDICA A/S’s CANNASEN Pain Patch receives approval from Israel’s Ministry of Health and is set to debut as the first-ever OTC product with CBD in Israel 405

6.58 May 15, 2023: Solasia Pharma announces consolidated financial results for the first three months of the fiscal year ending December 31, 2023 406

6.59 May 11, 2023: Medtronic to announce financial results for its fourth quarter and full fiscal year 2023 406

6.60 May 10, 2023: Camurus: Resolutions at the annual general meeting 2023 407

6.61 May 09, 2023: 3M annual meeting highlights business portfolio, innovation, and actions to drive future performance 408

6.62 May 08, 2023: DURECT reports Q1 2023 financial results and business update 409

6.63 May 02, 2023: Lannett Files Prepackaged Chapter 11 Cases to Significantly Strengthen Financial Position 410

6.64 May 01, 2023: Aequus Provides General update and fiscal 2022 financial results 411

6.65 Apr 28, 2023: Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023 411

6.66 Apr 28, 2023: Nanologica Announces Interim Report Q1 2023 412

6.67 Apr 26, 2023: Nitto Denko announces supplementary data of consolidated financial statements for the year ended

Table

Transdermal Drug Delivery – Pipeline Products by Stage of Development 31

Transdermal Drug Delivery – Pipeline Products by Segment 32

Transdermal Drug Delivery – Pipeline Products by Territory 33

Transdermal Drug Delivery – Pipeline Products by Regulatory Path 35

Transdermal Drug Delivery – Pipeline Products by Estimated Approval Date 36

Transdermal Drug Delivery – Ongoing Clinical Trials 37

Transdermal Drug Delivery Companies – Pipeline Products by Stage of Development 38

Transdermal Drug Delivery – Pipeline Products by Stage of Development 45

3P Biotechnologies Inc Pipeline Products & Ongoing Clinical Trials Overview 53

PolyC – Product Status 53

PolyC – Product Description 53

4P Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 54

4P Apomorphine Transdermal Patch – Product Status 54

4P Apomorphine Transdermal Patch – Product Description 55

4P Chronic Pain Transdermal Patch – Product Status 55

4P Chronic Pain Transdermal Patch – Product Description 55

4P Clonidine Transdermal Patch – Product Status 55

4P Clonidine Transdermal Patch – Product Description 56

4P Diabetes Transdermal Patch – Product Status 56

4P Diabetes Transdermal Patch – Product Description 56

4P Lidocaine Transdermal Patch – Product Status 56

4P Lidocaine Transdermal Patch – Product Description 57

4P Migraine Transdermal Patch – Product Status 57

4P Migraine Transdermal Patch – Product Description 57

4P Scopolamine Transdermal Patch – Product Status 57

4P Scopolamine Transdermal Patch – Product Description 58

Aversa – Product Status 58

Aversa – Product Description 58

Aversa Buprenorphine Patch – Product Status 59

Aversa Buprenorphine Patch – Product Description 59

Aversa Methylphenidate Patch – Product Status 59

Aversa Methylphenidate Patch – Product Description 60

Transdermal Exenatide Patch – Product Status 60

Transdermal Exenatide Patch – Product Description 60

Transdermal FSH Patch – Product Status 61

Transdermal FSH Patch – Product Description 61

Abionic SA Pipeline Products & Ongoing Clinical Trials Overview 62

COVID-19 DNA Vaccine Microneedle Patch – Product Status 62

COVID-19 DNA Vaccine Microneedle Patch – Product Description 62

Actuated Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 63

GentleDispense System – Product Status 63

GentleDispense System – Product Description 63

Adynxx Inc Pipeline Products & Ongoing Clinical Trials Overview 64

Transdermal Postherpetic Neuralgia Pain Patch – Product Status 64

Transdermal Postherpetic Neuralgia Pain Patch – Product Description 64

Aequus Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 65

AQS1301 – Product Status 65

AQS1301 – Product Description 66

AQS1302 – Product Status 66

AQS1302 – Product Description 66

AQS1303 – Product Status 67

AQS1303 – Product Description 67

AQS1304 – Product Status 67

AQS1304 – Product Description 68

AerMedX Ltd Pipeline Products & Ongoing Clinical Trials Overview 69

Deposition System – Product Status 69

Deposition System – Product Description 69

Agile Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 70

AG200-ER Patch – Product Status 70

AG200-ER Patch – Product Description 71

AG200-SP Patch – Product Status 71

AG200-SP Patch – Product Description 71

AG890 Patch – Product Status 72

AG890 Patch – Product Description 72

Allergan Ltd Pipeline Products & Ongoing Clinical Trials Overview 73

Nanotechnology-Based Transdermal Delivery System – Product Status 73

Nanotechnology-Based Transdermal Delivery System – Product Description 73

Norethindrone Transdermal Delivery System – Product Status 74

Norethindrone Transdermal Delivery System – Product Description 74

American Chemical Society Pipeline Products & Ongoing Clinical Trials Overview 75

COVID-19 Microneedle Patch – Product Status 75

COVID-19 Microneedle Patch – Product Description 75

AMW GmbH Pipeline Products & Ongoing Clinical Trials Overview 76

Anastrozole Transdermal Patch – Product Status 76

Anastrozole Transdermal Patch – Product Description 76

Amzell BV Pipeline Products & Ongoing Clinical Trials Overview 77

AMZ001 – Product Status 77

AMZ001 – Product Description 77

Apogee Technology Inc Pipeline Products & Ongoing Clinical Trials Overview 78

PyraDerm – Product Status 78

PyraDerm – Product Description 78

Asahi Kasei Pharma Corp Pipeline Products & Ongoing Clinical Trials Overview 79

Teribone Microneedle Patch System – Product Status 79

Teribone Microneedle Patch System – Product Description 79

ASCIL Biopharm Pipeline Products & Ongoing Clinical Trials Overview 80

Minimally Invasive Transdermal System – Product Status 80

Minimally Invasive Transdermal System – Product Description 80

Avecho Biotechnology Ltd Pipeline Products & Ongoing Clinical Trials Overview 81

TPM – Diclofenac Patch – Product Status 81

TPM – Diclofenac Patch – Product Description 81

TPM – Lidocaine Patch – Product Status 82

TPM – Lidocaine Patch – Product Description 82

TPM – Oxycodone Patch – Product Status 82

TPM – Oxycodone Patch – Product Description 83

TPM – Oxymorphone Patch – Product Status 83

TPM – Oxymorphone Patch – Product Description 83

Avro Life Sciences Pipeline Products & Ongoing Clinical Trials Overview 84

OmniDerm – Product Status 84

OmniDerm – Product Description 84

Remdesivir Transdermal Patch – Product Status 85

Remdesivir Transdermal Patch – Product Description 85

BioNxt Solutions Inc. Pipeline Products & Ongoing Clinical Trials Overview 86

Rotigotine Transdermal Patch – Product Status 86

Rotigotine Transdermal Patch – Product Description 86

BioNxt Solutions Inc. – Ongoing Clinical Trials Overview 87

Rotigotine Transdermal Patch – A Human Clinical Pilot Study to Assess the Relative Bioavailability, Skin Adhesion and Skin Tolerance of Rotigotine Transdermal Patch 88

Boryung Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 89

Donepezil Patch – Product Status 89

Donepezil Patch – Product Description 89

Burke Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 90

BLU402 Hydrogel Patch Wart Kit – Product Status 90

BLU402 Hydrogel Patch Wart Kit – Product Description 90

Drug Delivery Patch – Product Status 91

Drug Delivery Patch – Product Description 91

Candesant Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 92

Bi-Layer Patch – Facial Hyperhidrosis – Product Status 92

Bi-Layer Patch – Facial Hyperhidrosis – Product Description 92

Bi-Layer Patch – Palmar Hyperhidrosis – Product Status 93

Bi-Layer Patch – Palmar Hyperhidrosis – Product Description 93

Bi-Layer Patch – Plantar Hyperhidrosis – Product Status 93

Bi-Layer Patch – Plantar Hyperhidrosis – Product Description 94

Brella – Product Status 94

Brella – Product Description 94

Candesant Biomedical Inc – Ongoing Clinical Trials Overview 95

Brella – An Evaluation of the Safety and Effectiveness of the N-SWEAT Patch for the Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating 96

Carnegie Mellon University Pipeline Products & Ongoing Clinical Trials Overview 97

Bioresorbable Drug Delivery Patch – Product Status 97

Bioresorbable Drug Delivery Patch – Product Description 97

Cassava Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 98

FENROCK – Product Status 98

FENROCK – Product Description 98

CB Scientific Inc Pipeline Products & Ongoing Clinical Trials Overview 99

Pain-Patch – Product Status 99

Pain-Patch – Product Description 99

Cerimon Pharmaceuticals, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 100

Topical Diclofenac Patch – Product Status 100

Topical Diclofenac Patch – Product Description 100

Chrono Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 101

Biologically-Timed Drug Delivery Device – Product Status 101

Biologically-Timed Drug Delivery Device – Product Description 101

Cipla Ltd Pipeline Products & Ongoing Clinical Trials Overview 102

Tizanidine Transdermal Patch – Product Status 102

Tizanidine Transdermal Patch – Product Description 102

Clexio Biosciences Ltd Pipeline Products & Ongoing Clinical Trials Overview 103

CLE-200 – Product Status 103

CLE-200 – Product Description 103

Corium Inc Pipeline Products & Ongoing Clinical Trials Overview 104

Corplex Memantine Transdermal System – Product Status 104

Corplex Memantine Transdermal System – Product Description 104

Corplex Ropinirole Transdermal System – Product Status 105

Corplex Ropinirole Transdermal System – Product Description 105

MicroCor hPTH(1-34) Transdermal System – Product Status 105

MicroCor hPTH(1-34) Transdermal System – Product Description 106

MicroCor Zolmitriptan Transdermal System – Product Status 106

MicroCor Zolmitriptan Transdermal System – Product Description 106

MicroJet – Product Status 107

MicroJet – Product Description 107

Daewon Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 108

DW-1022 – Product Status 108

DW-1022 – Product Description 108

Daewon Pharmaceutical Co Ltd – Ongoing Clinical Trials Overview 109

DW-1022 – A Study To Assess the Effects of the DW-1022 for Obesity Treatment 110

Daewoong Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 111

Donepezil Patch – Product Status 111

Donepezil Patch – Product Description 111

DBV Technologies SA Pipeline Products & Ongoing Clinical Trials Overview 112

Viaskin Milk – Product Status 112

Viaskin Milk – Product Description 113

Viaskin Peanut Allergy Patch – 1-3 Years – Product Status 113

Viaskin Peanut Allergy Patch – 1-3 Years – Product Description 113

Viaskin Peanut Allergy Patch – 4-11 Years – Product Status 114

Viaskin Peanut Allergy Patch – 4-11 Years – Product Description 114

Viaskin Peanut Allergy Patch – Adolescents and Adults – Product Status 114

Viaskin Peanut Allergy Patch – Adolescents and Adults – Product Description 115

Viaskin rPT – Product Status 115

Viaskin rPT – Product Description 115

DBV Technologies SA – Ongoing Clinical Trials Overview 116

Viaskin Peanut Allergy Patch – 1-3 Years – A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age 117

Viaskin Peanut Allergy Patch – 1-3 Years – Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut 117

Viaskin Peanut Allergy Patch – 4-11 Years – A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy With DBV712 250 µg in 4-7-year-old Children With Peanut Allergy (VITESSE) 118

Viaskin Peanut Allergy Patch – 4-11 Years – Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy 118

DD Therapeutics LLC (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 119

Transdermal Delivery System – Product Status 119

Transdermal Delivery System – Product Description 119

Delpor Inc Pipeline Products & Ongoing Clinical Trials Overview 120

Risperidone Subcutaneous Implant – Product Status 120

Risperidone Subcutaneous Implant – Product Description 120

Tizanidine Implant – Product Status 121

Tizanidine Implant – Product Description 121

Dermisonics Inc Pipeline Products & Ongoing Clinical Trials Overview 122

U-Strip – Product Status 122

U-Strip – Product Description 122

Dharma Therapeutics, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 123

Iontophoretic Drug Delivery Patch – Product Status 123

Iontophoretic Drug Delivery Patch – Product Description 123

Diomics Corp Pipeline Products & Ongoing Clinical Trials Overview 124

Diocheck Antibody Indicator – Product Status 124

Diocheck Antibody Indicator – Product Description 124

Dong-A ST Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 125

Donepezil Transdermal Patch – Product Status 125

Donepezil Transdermal Patch – Product Description 125

Drexel University Pipeline Products & Ongoing Clinical Trials Overview 126

Ultrasonically Assisted Transcutaneous Drug Delivery Device – Product Status 126

Ultrasonically Assisted Transcutaneous Drug Delivery Device – Product Description 126

DURECT Corp Pipeline Products & Ongoing Clinical Trials Overview 127

Eladur – Product Status 127

Eladur – Product Description 127

TRANSDUR – Sufentanil – Product Status 128

TRANSDUR – Sufentanil – Product Description 128

Echo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 129

Prelude SkinPrep System – Product Status 129

Prelude SkinPrep System – Product Description 129

Emplicure AB Pipeline Products & Ongoing Clinical Trials Overview 130

Micro-Needle Patch – Product Status 130

Micro-Needle Patch – Product Description 130

Endo International Plc Pipeline Products & Ongoing Clinical Trials Overview 131

Rivastigmine Patch – Product Status 131

Rivastigmine Patch – Product Description 131

Endomimetics LLC Pipeline Products & Ongoing Clinical Trials Overview 132

AVF Gel – Product Status 132

AVF Gel – Product Description 132

Extend Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 133

Non-Invasive Needle-Free Skin Patch – Product Status 133

Non-Invasive Needle-Free Skin Patch – Product Description 133

Fe3 Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 134

Fe3 Patch – Product Status 134

Fe3 Patch – Product Description 134

Futura Medical Plc Pipeline Products & Ongoing Clinical Trials Overview 135

Eroxon – Product Status 135

Eroxon – Product Description 135

MED3000 – Rx – Product Status 136

MED3000 – Rx – Product Description 136

Futura Medical Plc – Ongoing Clinical Trials Overview 137

MED3000 – Rx – MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction 138

Georgetown University Pipeline Products & Ongoing Clinical Trials Overview 139

Passive Transdermal Drug Delivery Patch – Parkinson’s Disease – Product Status 139

Passive Transdermal Drug Delivery Patch – Parkinson’s Disease – Product Description 139

Georgia Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 140

Micron – Scale Arcing Device – Product Status 140

Micron – Scale Arcing Device – Product Description 140

Microneedle Patch – Measles – Product Status 141

Microneedle Patch – Measles – Product Description 141

Microneedle Patch – Polio – Product Status 141

Microneedle Patch – Polio – Product Description 142

Microneedle Patch – Rubella – Product Status 142

Microneedle Patch – Rubella – Product Description 142

Georgia State University Pipeline Products & Ongoing Clinical Trials Overview 143

Microneedle Patch – Flu – Product Status 143

Microneedle Patch – Flu – Product Description 143

GlobeStar Therapeutics Corp Pipeline Products & Ongoing Clinical Trials Overview 144

Transdermal PGE-1 Patch – Product Status 144

Transdermal PGE-1 Patch – Product Description 144

Henley Ion LLC Pipeline Products & Ongoing Clinical Trials Overview 145

Anesthesia Delivery Dental Device – Product Status 145

Anesthesia Delivery Dental Device – Product Description 145

Hera Health Solutions Pipeline Products & Ongoing Clinical Trials Overview 146

Biodegradable Subcutaneous Buprenorphine Releasing Implant – Product Status 146

Biodegradable Subcutaneous Buprenorphine Releasing Implant – Product Description 146

Hisamitsu Pharmaceutical Co Inc Pipeline Products & Ongoing Clinical Trials Overview 147

HP-1030 Adhesive Skin Patch – Product Status 147

HP-1030 Adhesive Skin Patch – Product Description 147

HP-5000 Topical Patch – Product Status 148

HP-5000 Topical Patch – Product Description 148

HTU-520 Patch – Product Status 148

HTU-520 Patch – Product Description 149

I M Sechenov Moscow State Medical University Pipeline Products & Ongoing Clinical Trials Overview 150

Anti-Cancer Patch – Product Status 150

Anti-Cancer Patch – Product Description 150

Icure Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 151

Donepezil Dementia Patch – Product Status 151

Donepezil Dementia Patch – Product Description 152

Exenatide Patch – Product Status 152

Exenatide Patch – Product Description 152

Fentanyl Pain Relief Patch – Product Status 153

Fentanyl Pain Relief Patch – Product Description 153

Fomoterol Patch – Product Status 153

Fomoterol Patch – Product Description 154

Melatonin Patch – Product Status 154

Melatonin Patch – Product Description 154

Physostigmine Patch – Product Status 155

Physostigmine Patch – Product Description 155

Pramipexole Parkinson’s Patch – Product Status 155

Pramipexole Parkinson’s Patch – Product Description 156

Rotigotine Patch – Product Status 156

Rotigotine Patch – Product Description 156

Varenicline Patch – Product Status 157

Varenicline Patch – Product Description 157

ImmunoMatrix LLC Pipeline Products & Ongoing Clinical Trials Overview 158

Dermal Skin Patch Delivery System – Product Status 158

Dermal Skin Patch Delivery System – Product Description 158

ImmuPatch Pipeline Products & Ongoing Clinical Trials Overview 159

Coated ImmuPatch – Product Status 159

Coated ImmuPatch – Product Description 159

Dissolvable ImmuPatch – Product Status 159

Dissolvable ImmuPatch – Product Description 160

Indian Institute of Science Pipeline Products & Ongoing Clinical Trials Overview 161

Drug Delivery Patch – Product Status 161

Drug Delivery Patch – Product Description 161

Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview 162

Poly (n-Vinyl Caprolactam) Transdermal Drug Delivery System – Product Status 162

Poly (n-Vinyl Caprolactam) Transdermal Drug Delivery System – Product Description 162

Indian Institute of Technology Hyderabad Pipeline Products & Ongoing Clinical Trials Overview 163

Transdermal Mucoadhesive Patch – Product Status 163

Transdermal Mucoadhesive Patch – Product Description 163

InMed Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 164

INM-755 – Drug Delivery Device – Product Status 164

INM-755 – Drug Delivery Device – Product Description 164

MiDROPS INM-088 Drug Delivery Device – Product Status 165

MiDROPS INM-088 Drug Delivery Device – Product Description 165

Institute of Materials Research & Engineering Pipeline Products & Ongoing Clinical Trials Overview 166

Skin Breaching Device – Product Status 166

Skin Breaching Device – Product Description 166

Intercell AG (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 167

Travelers Diarrhea Vaccine Patch – Product Status 167

Travelers Diarrhea Vaccine Patch – Product Description 167

Interstitial NS Pipeline Products & Ongoing Clinical Trials Overview 168

NanoMAP – Product Status 168

NanoMAP – Product Description 168

Isis Biopolymer Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 169

Gentle Touch – Product Status 169

Gentle Touch – Product Description 169

IsisIQ CLI – Product Status 169

IsisIQ CLI – Product Description 170

James J. Peters VA Medical Center Pipeline Products & Ongoing Clinical Trials Overview 171

Iontophoresis Patch – Product Status 171

Iontophoresis Patch – Product Description 171

Janisys Pipeline Products & Ongoing Clinical Trials Overview 172

Janisys Drug Delivery System – Product Status 172

Janisys Drug Delivery System – Product Description 172

Jiaxing Xinwen Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 173

Transdermal Drug Delivery System – Neurology – Product Status 173

Transdermal Drug Delivery System – Neurology – Product Description 173

Transdermal Drug Delivery System – Pain – Product Status 174

Transdermal Drug Delivery System – Pain – Product Description 174

Jubilee Biotech Pipeline Products & Ongoing Clinical Trials Overview 175

JUBIwatch – Product Status 175

JUBIwatch – Product Description 175

Karolinska Institute Pipeline Products & Ongoing Clinical Trials Overview 176

Microneedle Patch – MRSA – Product Status 176

Microneedle Patch – MRSA – Product Description 176

Kindeva Drug Delivery LP Pipeline Products & Ongoing Clinical Trials Overview 177

Hollow Microstructured Transdermal System – Product Status 177

Hollow Microstructured Transdermal System – Product Description 177

Solid Microneedles Transdermal System – Product Status 178

Solid Microneedles Transdermal System – Product Description 178

KTH Royal Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 179

Microneedle Skin Patch – Product Status 179

Microneedle Skin Patch – Product Description 179

Leo Pharma AS Pipeline Products & Ongoing Clinical Trials Overview 180

Microneedle Patch – Psoriasis – Product Status 180

Microneedle Patch – Psoriasis – Product Description 180

Livzon Pharmaceutical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 181

Asenapine TTS – Product Status 181

Asenapine TTS – Product Description 181

Lohmann Therapie-Systeme AG Pipeline Products & Ongoing Clinical Trials Overview 182

Intradermal Microneedle Patch – Product Status 182

Intradermal Microneedle Patch – Product Description 182

Smart Patch – Product Status 183

Smart Patch – Product Description 183

Luye Pharma Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 184

Apleek – Product Status 184

Apleek – Product Description 184

Rivalif – Product Status 185

Rivalif – Product Description 185

Magnetar Medical Devices Ltd Pipeline Products & Ongoing Clinical Trials Overview 186

RATO Patch – Product Status 186

RATO Patch – Product Description 186

Massachusetts Institute of Technology Pipeline Products & Ongoing Clinical Trials Overview 187

Microneedle Patch – Melanoma – Product Status 187

Microneedle Patch – Melanoma – Product Description 187

Wearable Ultrasound Patch – Product Status 188

Wearable Ultrasound Patch – Product Description 188

Mayne Pharma Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 189

Motion Sickness Transdermal Delivery System Patch – Product Status 189

Motion Sickness Transdermal Delivery System Patch – Product Description 189

Medherant Ltd Pipeline Products & Ongoing Clinical Trials Overview 190

Diclofenac TEPI Patch – Product Status 190

Diclofenac TEPI Patch – Product Description 190

Donepezil TEPI Patch – Product Status 191

Donepezil TEPI Patch – Product Description 191

Dronabinol TEPI Patch – Product Status 191

Dronabinol TEPI Patch – Product Description 192

Ibuprofen TEPI Patch – Product Status 192

Ibuprofen TEPI Patch – Product Description 192

Lidocaine TEPI Patch – Product Status 193

Lidocaine TEPI Patch – Product Description 193

Memantine TEPI Patch – Product Status 193

Memantine TEPI Patch – Product Description 194

Methyl Salicylate TEPI Patch – Product Status 194

Methyl Salicylate TEPI Patch – Product Description 194

MEDRx Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 195

Etoreat – Product Status 195

Etoreat – Product Description 196

Lydolyte – Product Status 196

Lydolyte – Product Description 196

MRX-1OXT Patch – Product Status 197

MRX-1OXT Patch – Product Description 197

MRX-4TZT Patch – Product Status 197

MRX-4TZT Patch – Product Description 198

MRX-7LAT Lidocaine Patch – Product Status 198

MRX-7LAT Lidocaine Patch – Product Description 198

MRX-7MLL – Product Status 199

MRX-7MLL – Product Description 199

MRX-9FLT Patch – Product Status 199

MRX-9FLT Patch – Product Description 200

MedRx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 201

KENZAN Microneedle Array – Product Status 201

KENZAN Microneedle Array – Product Description 201

Microdermics Inc Pipeline Products & Ongoing Clinical Trials Overview 202

Microneedle Drug Delivery System – Product Status 202

Microneedle Drug Delivery System – Product Description 202

Micron Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview 203

Microneedle Patch – Contraception – Product Status 203

Microneedle Patch – Contraception – Product Description 203

Microneedle Patch – Virus Infection – Product Status 204

Microneedle Patch – Virus Infection – Product Description 204

Micropoint Technologies Pte Ltd Pipeline Products & Ongoing Clinical Trials Overview 205

Drug-Coated Micropoint Patch – Product Status 205

Drug-Coated Micropoint Patch – Product Description 205

Mineed Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 206

Detachable and Dissolvable Microneedle Patch – Product Status 206

Detachable and Dissolvable Microneedle Patch – Product Description 206

Mycrodose Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 207

Psilocin Transdermal Drug Delivery System – Product Status 207

Psilocin Transdermal Drug Delivery System – Product Description 207

Transdermal Drug Delivery System – LSD – Product Status 208

Transdermal Drug Delivery System – LSD – Product Description 208

MyLife Technologies Pipeline Products & Ongoing Clinical Trials Overview 209

Ceramic Vaccine Patch – Product Status 209

Ceramic Vaccine Patch – Product Description 209

Nanyang Technological University Pipeline Products & Ongoing Clinical Trials Overview 210

Skin Pressure Device – Product Status 210

Skin Pressure Device – Product Description 210

National Dental Centre Singapore Pipeline Products & Ongoing Clinical Trials Overview 211

MN Patch – Product Status 211

MN Patch – Product Description 211

National University of Singapore Pipeline Products & Ongoing Clinical Trials Overview 212

Microneedle Granule – Drug Delivery – Product Status 212

Microneedle Granule – Drug Delivery – Product Description 212

Microneedle Skin Patch – Product Status 213

Microneedle Skin Patch – Product Description 213

Nemaura Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 214

Memspatch – Product Status 214

Memspatch – Product Description 215

Microneedle Drug Delivery Device – Product Status 215

Microneedle Drug Delivery Device – Product Description 215

Micropatch – Product Status 215

Micropatch – Product Description 216

Mycrolator – Product Status 216

Mycrolator – Product Description 216

Transdermal Patch – Alzheimer’s Disease – Product Status 217

Transdermal Patch – Alzheimer’s Disease – Product Description 217

Transdermal Patch – Buprenorphine – Product Status 217

Transdermal Patch – Buprenorphine – Product Description 217

Transdermal Patch – Diclofenac – Product Status 218

Transdermal Patch – Diclofenac – Product Description 218

Transdermal Patch – Hypertension – Product Status 218

Transdermal Patch – Hypertension – Product Description 218

Transdermal Patch – Nicotine – Product Status 219

Transdermal Patch – Nicotine – Product Description 219

Transdermal Patch – Parkinson’s Disease – Product Status 219

Transdermal Patch – Parkinson’s Disease – Product Description 219

Transdermal Patch – Rivastigmine – Product Status 220

Transdermal Patch – Rivastigmine – Product Description 220

NeuroDerm Ltd Pipeline Products & Ongoing Clinical Trials Overview 221

ND0601 Dermal Patch – Product Status 221

ND0601 Dermal Patch – Product Description 221

ND0611 Dermal Patch – Product Status 222

ND0611 Dermal Patch – Product Description 222

Nexgel Inc Pipeline Products & Ongoing Clinical Trials Overview 223

Diclofenac Hydrogel Patch – Product Status 223

Diclofenac Hydrogel Patch – Product Description 223

Nitto Denko Corp Pipeline Products & Ongoing Clinical Trials Overview 224

Transdermal Enoxaparin Sodium Patch – Product Status 224

Transdermal Enoxaparin Sodium Patch – Product Description 224

Transdermal Fentanyl Citrate Patch – Product Status 225

Transdermal Fentanyl Citrate Patch – Product Description 225

Transdermal Protein Patch – Product Status 225

Transdermal Protein Patch – Product Description 226

North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview 227

Antibody Delivery Microneedle Patch – Product Status 227

Antibody Delivery Microneedle Patch – Product Description 227

Intraconazole Microneedle Patch – Product Status 228

Intraconazole Microneedle Patch – Product Description 228

Skin Patch – Melanoma – Product Status 228

Skin Patch – Melanoma – Product Description 228

Nova Graphene Ballistics Inc Pipeline Products & Ongoing Clinical Trials Overview 229

Anti-Addiction Patch – Product Status 229

Anti-Addiction Patch – Product Description 229

Noven Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 230

Lidocaine Topical Patch – Product Status 230

Lidocaine Topical Patch – Product Description 230

NutriBand Inc Pipeline Products & Ongoing Clinical Trials Overview 231

Ciprofloxacin Transdermal Patch – Product Status 231

Ciprofloxacin Transdermal Patch – Product Description 231

TD00A1 – Transdermal Drug Delivery System – Product Status 232

TD00A1 – Transdermal Drug Delivery System – Product Description 232

TD00G1 – Transdermal Drug Delivery System – Product Status 232

TD00G1 – Transdermal Drug Delivery System – Product Description 233

TD0CD1/TD0CD2 – Transdermal Drug Delivery System – Product Status 233

TD0CD1/TD0CD2 – Transdermal Drug Delivery System – Product Description 233

TD0ID1 – Transdermal Drug Delivery System – Product Status 234

TD0ID1 – Transdermal Drug Delivery System – Product Description 234

TD0IJD – Transdermal Drug Delivery System – Product Status 234

TD0IJD – Transdermal Drug Delivery System – Product Description 234

Nuvo Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 235

Alprazolam Patch – Product Status 235

Alprazolam Patch – Product Description 235

Ohio State University Pipeline Products & Ongoing Clinical Trials Overview 236

4-HPR Patch – Product Status 236

4-HPR Patch – Product Description 236

Transdermal Wound Dressing – Product Status 237

Transdermal Wound Dressing – Product Description 237

Osprey Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 238

Limb Recovery System – Product Status 238

Limb Recovery System – Product Description 238

Pantec Biosolutions AG Pipeline Products & Ongoing Clinical Trials Overview 239

P.L.E.A.S.E. Diclofenac/Lidocaine Device – Product Status 239

P.L.E.A.S.E. Diclofenac/Lidocaine Device – Product Description 239

P.L.E.A.S.E. IT Device – Product Status 240

P.L.E.A.S.E. IT Device – Product Description 240

P.L.E.A.S.E. Mobile – Product Status 240

P.L.E.A.S.E. Mobile – Product Description 241

P.L.E.A.S.E. Private – Product Status 241

P.L.E.A.S.E. Private – Product Description 241

P.L.E.A.S.E. RNAi – Product Status 241

P.L.E.A.S.E. RNAi – Product Description 242

PassPort Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 243

PassPort System – Product Status 243

PassPort System – Product Description 243

Pebble Inc Pipeline Products & Ongoing Clinical Trials Overview 244

Smart Drug Delivery System – Product Status 244

Smart Drug Delivery System – Product Description 244

PharmaTher Holdings Ltd Pipeline Products & Ongoing Clinical Trials Overview 245

DMT MN-Patch – Major Depressive Disorder – Product Status 245

DMT MN-Patch – Major Depressive Disorder – Product Description 245

MacroDose-MN Patch – Product Status 246

MacroDose-MN Patch – Product Description 246

MDMA MN Patch – Mental Disorders – Product Status 246

MDMA MN Patch – Mental Disorders – Product Description 247

MicroDose-MN Patch – Product Status 247

MicroDose-MN Patch – Product Description 247

PHARMAPATCH – Product Status 248

PHARMAPATCH – Product Description 248

Privo Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 249

PRV111 – Product Status 249

PRV111 – Product Description 249

Prometheon Pharma LLC Pipeline Products & Ongoing Clinical Trials Overview 250

HeatWave Patch – Product Status 250

HeatWave Patch – Product Description 250

TruePatch – Basal Insulin – Product Status 251

TruePatch – Basal Insulin – Product Description 251

TruePatch – Rapid-Acting (Bolus) Insulin – Product Status 251

TruePatch – Rapid-Acting (Bolus) Insulin – Product Description 252

Purdue University Pipeline Products & Ongoing Clinical Trials Overview 253

Flexible Elastomer Patch – Product Status 253

Flexible Elastomer Patch – Product Description 253

Microneedle Patch – Wound Oxygenation – Product Status 254

Microneedle Patch – Wound Oxygenation – Product Description 254

Pump For Drug-Delivery Patch – Product Status 254

Pump For Drug-Delivery Patch – Product Description 255

Quadmedicine Pipeline Products & Ongoing Clinical Trials Overview 256

Microneedle Drug Delivery Device – Obesity – Product Status 256

Microneedle Drug Delivery Device – Obesity – Product Description 256

Microneedle Drug Delivery Device – Osteoporosis – Product Status 257

Microneedle Drug Delivery Device – Osteoporosis – Product Description 257

QMM-P010 – Product Status 257

QMM-P010 – Product Description 258

QMV-P007 – Product Status 258

QMV-P007 – Product Description 258

QMV-P008 – Product Status 259

QMV-P008 – Product Description 259

Quoin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 260

QRX001 – Product Status 260

QRX001 – Product Description 260

QRX002 – Product Status 261

QRX002 – Product Description 261

Radius Health Inc Pipeline Products & Ongoing Clinical Trials Overview 262

Tymlos Patch – Product Status 262

Tymlos Patch – Product Description 262

Rescue Biomedical

Figures

Transdermal Drug Delivery – Pipeline Products by Stage of Development 30_x000D_

Transdermal Drug Delivery – Pipeline Products by Segment 31_x000D_

Transdermal Drug Delivery – Pipeline Products by Territory 32_x000D_

Transdermal Drug Delivery – Pipeline Products by Regulatory Path 34_x000D_

Transdermal Drug Delivery – Pipeline Products by Estimated Approval Date 36_x000D_

Transdermal Drug Delivery – Ongoing Clinical Trials 37_x000D_

Frequently asked questions

Transdermal Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Transdermal Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Transdermal Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Transdermal Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.